Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TPI-120 (Pegfilgrastim) PK and Safety Study
NCT07416955Phase 1Completed
- Sponsor
- Kashiv BioSciences
- Start
- Apr 2025
- Primary completion
- Oct 2025
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pegfilgrastim-apgf in neutropenia (2 arms), sponsored by Kashiv BioSciences. Primary endpoints: Maximum Plasma Concentration, Area Under the Curve to the last measurable concentration and 1 more. Started Apr 2025; status: completed.
02
Drugs
pegfilgrastim-apgf
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT07416955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07416955.